Tilray | TRLY - Operating Profit


Tilray reported $-20.01M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acasti Pharma USD -2.53M 560K Sep/2025
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Aurora Cannabis CAD -10.03M 25.76M Mar/2026
Avita Medical AUD -10.41M 742K Dec/2025
Canopy Growth CAD -27.47M 14.81M Mar/2026
Cronos Group USD -1.45M 5.61M Mar/2026
Dianthus Therapeutics USD -46.53M 23.01M Mar/2026
Divis Laboratories Ltd INR 8.14B 420M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
IQVIA Holdings USD 565M 2.11B Mar/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Moderna USD -1.39B 531M Mar/2026
Organigram Holdings CAD -9.79M 10.33M Mar/2026
Organon & Co USD 266M 49M Mar/2026
Revvity USD 82.77M 63.06M Mar/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD -20.2M 137.3M Mar/2026
Xeris Pharmaceuticals USD 7.92M 8.86M Mar/2026
Zealand Pharma A/S -707.05M 245.73M Dec/2025